{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-135082","form_type":"8-K","ticker":"KPTI","cik":"0001503802","company_name":"Karyopharm Therapeutics Inc.","filed_at":"2023-05-04T23:59:59+00:00","discovered_at":"2026-05-14T18:03:39.102094+00:00","generated_at":"2026-06-15T21:42:04.765899+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Karyopharm cuts FY2023 revenue guidance on higher patient assistance; Q1 net loss narrows","bullets":["Q1 total revenue $38.7M, XPOVIO net product revenue $28.3M flat YoY; net loss $34.1M ($0.30/sh) vs $41.4M loss YoY.","FY2023 total revenue guidance lowered to $145-160M (from $160-175M); XPOVIO net product revenue now $110-125M due to increased patient assistance programs.","Non-GAAP R&D and SG&A expense guidance reduced to $245-260M; cash runway reiterated to late 2025.","Phase 1 selinexor+ruxolitinib in front-line MF: 83.3% SVR35 at wk12, 80% TSS50; Phase 3 planned 1H 2023.","Eltanexor in Hr R/R MDS interim: median OS 8.7 months; UK marketing authorization granted for NEXPOVIO combo."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-135082","json":"https://secwatch.observer/filing/0001193125-23-135082.json","markdown":"https://secwatch.observer/filing/0001193125-23-135082.md","text":"https://secwatch.observer/filing/0001193125-23-135082.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1503802/000119312523135082/0001193125-23-135082-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1503802/000119312523135082/d236538d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-15T21:42:04.765899+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"eab9b014803669299db9e50cf6a9fd81a3b6b80e","claim":"Karyopharm Therapeutics Inc. reported First Quarter 2023 results: revenue $38.7 Million.","evidence_excerpt":"Karyopharm Reports First Quarter 2023 Financial Results and Highlights Recent Company Progress – Achieved First Quarter 2023 Total Revenues of $38.7 Million, including XPOVIO ® (selinexor) Net Product Revenue of $28.3 Million, Adversely Impacted by Increased Utilization of Patient Assistant Programs (PAP) and Higher Gross to Net; YoY Growth in Total Demand 1","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1503802/000119312523135082/0001193125-23-135082-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"First Quarter 2023"},{"label":"Revenue","value":"$38.7 Million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"ff1f6d6c02eb72845a581a3ec31fb0ab60e222af","claim":"Karyopharm Therapeutics Inc. reported Full Year 2023 results: revenue $145 Million to $160 Million. Guidance lowered.","evidence_excerpt":"Company Revises Full Year 2023 Total Revenue Guidance to $145 Million to $160 Million, Including Revised XPOVIO Net Product Revenue Guidance of $110 Million to $125 Million, Reflecting Increased Use of PAP – – Non-GAAP R&D and SG&A Expense Guidance Revised to $245 Million to $260 Million; Company Re-iterates Cash Runway to Late 2025","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1503802/000119312523135082/0001193125-23-135082-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"Full Year 2023"},{"label":"Revenue","value":"$145 Million to $160 Million"},{"label":"Guidance","value":"lowered"},{"label":"Result","value":"guidance update"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}